Can Chimeric Therapeutics' CLTX CAR T therapy blaze a trail in GBM treatment?


  • Clinical stage cell therapy company Chimeric Therapeutics is developing CLTX CAR T cell therapy, which has the ability to address the high unmet medical need of glioblastoma (GBM).
  • In May 2021, the oncology player commenced the second dose cohort in the Phase 1 trial of its CLTX CAR T therapy.
  • Chimeric will continue to provide Phase 1 clinical trial updates as the trial progress is on track. The Company is also actively planning to initiate Phase 2 registration trial.

ASX-listed oncology firm Chimeric Therapeutics Limited (ASX:CHM) is committed to bringing cell therapy to patients suffering from the most challenging form of cancer. CHM is focused on finding cures for the challenging indications and believes that innovative cellular therapies have the potential to do that.

DO READ: Chimeric Therapeutics bringing innovation to the fore with its CLTX CAR T Therapy

CLTX-CAR T-Cell Therapy

Chlorotoxin CAR T (CLTX CAR T) cell therapy uses a peptide found in scorpion venom -  chlorotoxin. It is a potential best-in-class CAR T cell therapy, which can tackle the high unmet medical need of patients suffering from recurrent or progressive glioblastoma (GBM). Research to develop the intellectual property (IP) covering this revolutionary CAR T cell therapy was conducted at the City of Hope.

Preclinical studies demonstrated that CLTX CAR T cells have potent antitumour activity against GBM, a fast-growing and aggressive brain cancer.

Currently, Chimeric Therapeutics is conducting CLTX CAR T therapy clinical trials at the City of Hope. On 24 May 2021, the Company announced the commencement of the second dose cohort in Phase 1 clinical trial. CHM highlighted that the second cohort introduces dual routes of administration of CLTX CAR T cells [intracranial intratumoral (ICT) and intracranial intraventricular (ICV) dosing].

On the initiation of second dose cohort of CLTX Phase 1 trial, Jennifer Chow, Chief Operating Officer of Chimeric Therapeutics, commented-

READ MORE: Another milestone as Chimeric Therapeutics’ (ASX:CHM) Phase 1 CLTX CAR T trial moves ahead

Novel Features of CLTX-CAR T-Cell Therapy

CLTX-CAR T-cell therapy uses chlorotoxin (CLTX) as the tumour-recognition domain, which identifies a multireceptor complex containing MMP2 to bind to GBM cells. Novel features of the therapy include-

Source: CHM-ASCO-Presentation (June 2021)

Chimeric expanding into additional tumours

The Company believes that chlorotoxin has plenty of promise outside of GBM, and preclinical models of CLTX therapy support the belief. Thus, Chimeric Therapeutics is now considering developing and designing a Phase 1 clinical trial to expand chlorotoxin into new indications. Currently, CHM focuses on melanoma, looking at colorectal cancer, prostate cancer, and small cell lung cancer.

MUST WATCH: Expert Talks With Kalkine || Ms Jennifer Chow, Chief Operating Officer of Chimeric Therapeutics

Source: CHM Presentation (18 March 2021)

Chimeric Therapeutics is well positioned and is building a team of experts, which can provide the necessary insights to address unique challenges in the cell therapy space.

ALSO READ: Meet the leadership team behind Chimeric Therapeutics’ innovative CLTX-CAR T therapy

Outlook: the way forward

The Company anticipates the rest of 2021 to be incredibly busy. With chlorotoxin, CHM will continue to provide Phase 1 clinical trial updates as the trial advances and remains on track. In addition, the oncology firm will be defining the Phase 2 trial manufacturing strategy and the clinical trial protocol for the Phase 2 registration trial.

Furthermore, the Company will also focus on establishing cell therapy expertise to enable rapid development as well as commercialisation of CLTX CAR T.

Source: CHM Presentation (June 2021)

On 24 June 2021, CHM shares were trading at AU$0.285 (at 02:18 PM AEST).

MUST READ: Using scorpion venom to treat tumours: A look at Chimeric Therapeutics' CLTX technology

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.



Top Penny Picks under 20 Cents to Fit Your Pocket! Get Exclusive Report on Penny Stocks For FREE Now.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK